$2.54T
Total marketcap
$193.21B
Total volume
BTC 49.92%     ETH 15.85%
Dominance

Arrowhead Pharmaceuticals ARWR Stock

28.14 USD {{ price }} -0.495054% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
3.49B USD
LOW - HIGH [24H]
27.21 - 28.36 USD
VOLUME [24H]
1.27M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.77 USD

Arrowhead Pharmaceuticals Price Chart

Arrowhead Pharmaceuticals ARWR Financial and Trading Overview

Arrowhead Pharmaceuticals stock price 28.14 USD
Previous Close 35.34 USD
Open 35.15 USD
Bid 0 USD x 800
Ask 0 USD x 900
Day's Range 34.53 - 35.82 USD
52 Week Range 23.09 - 48.48 USD
Volume 746.67K USD
Avg. Volume 1.02M USD
Market Cap 3.82B USD
Beta (5Y Monthly) 0.981338
PE Ratio (TTM) N/A
EPS (TTM) -2.77 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 62.21 USD

ARWR Valuation Measures

Enterprise Value 3.44B USD
Trailing P/E N/A
Forward P/E -12.540352
PEG Ratio (5 yr expected) -3.44
Price/Sales (ttm) 14.005155
Price/Book (mrq) 8.548194
Enterprise Value/Revenue 12.613
Enterprise Value/EBITDA -24.56

Trading Information

Arrowhead Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.981338
52-Week Change 22.73%
S&P500 52-Week Change 20.43%
52 Week High 48.48 USD
52 Week Low 23.09 USD
50-Day Moving Average 34.59 USD
200-Day Moving Average 33.18 USD

ARWR Share Statistics

Avg. Volume (3 month) 1.02M USD
Avg. Daily Volume (10-Days) 713.69K USD
Shares Outstanding 106.9M
Float 103.64M
Short Ratio 4.8
% Held by Insiders 4.92%
% Held by Institutions 68.70%
Shares Short 4.94M
Short % of Float 5.51%
Short % of Shares Outstanding 4.62%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:10

Financial Highlights

Fiscal Year

Fiscal Year Ends September 30, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End September 30, 2023

Profitability

Profit Margin -55.061%
Operating Margin (ttm) -55.24%
Gross Margin 100.00%
EBITDA Margin -51.35%

Management Effectiveness

Return on Assets (ttm) -11.81%
Return on Equity (ttm) -33.16%

Income Statement

Revenue (ttm) 272.8M USD
Revenue Per Share (ttm) 2.57 USD
Quarterly Revenue Growth (yoy) -3.59%
Gross Profit (ttm) 243.23M USD
EBITDA -140096000 USD
Net Income Avi to Common (ttm) -150207008 USD
Diluted EPS (ttm) -1.44
Quarterly Earnings Growth (yoy) 9.70%

Balance Sheet

Total Cash (mrq) 481M USD
Total Cash Per Share (mrq) 4.5 USD
Total Debt (mrq) 82.78M USD
Total Debt/Equity (mrq) 17.8 USD
Current Ratio (mrq) 6.596
Book Value Per Share (mrq) 4.181

Cash Flow Statement

Operating Cash Flow (ttm) -244739008 USD
Levered Free Cash Flow (ttm) -223982752 USD

Profile of Arrowhead Pharmaceuticals

Country United States
State CA
City Pasadena
Address 177 East Colorado Boulevard
ZIP 91105
Phone 626 304 3400
Website https://arrowheadpharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 397

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Q&A For Arrowhead Pharmaceuticals Stock

What is a current ARWR stock price?

Arrowhead Pharmaceuticals ARWR stock price today per share is 28.14 USD.

How to purchase Arrowhead Pharmaceuticals stock?

You can buy ARWR shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Arrowhead Pharmaceuticals?

The stock symbol or ticker of Arrowhead Pharmaceuticals is ARWR.

Which industry does the Arrowhead Pharmaceuticals company belong to?

The Arrowhead Pharmaceuticals industry is Biotechnology.

How many shares does Arrowhead Pharmaceuticals have in circulation?

The max supply of Arrowhead Pharmaceuticals shares is 123.9M.

What is Arrowhead Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Arrowhead Pharmaceuticals PE Ratio is now.

What was Arrowhead Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Arrowhead Pharmaceuticals EPS is -2.77 USD over the trailing 12 months.

Which sector does the Arrowhead Pharmaceuticals company belong to?

The Arrowhead Pharmaceuticals sector is Healthcare.

Arrowhead Pharmaceuticals ARWR included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD